Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.
- Author:
Hina J SHAH
1
;
Abhishek R KERALIYA
;
Jyothi P JAGANNATHAN
;
Sree Harsha TIRUMANI
;
Vikram R LELE
;
Pamela J DIPIRO
Author Information
- Publication Type:Review
- Keywords: Lymphoma; Diffuse large B cell lymphoma; FDG-positron emission tomography/CT; MRI
- MeSH: B-Lymphocytes*; Decision Making; Diagnosis; Lymphoma; Lymphoma, B-Cell*; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Musculoskeletal System; Nervous System; Positron-Emission Tomography; Positron-Emission Tomography and Computed Tomography; Radiography; Ultrasonography
- From:Korean Journal of Radiology 2017;18(1):54-70
- CountryRepublic of Korea
- Language:English
- Abstract: Diffuse large B cell lymphoma (DLBCL) is the most common histological subtype of Non-Hodgkin's lymphoma. As treatments continues to evolve, so do imaging strategies, and positron emission tomography (PET) has emerged as the most important imaging tool to guide oncologists in the diagnosis, staging, response assessment, relapse/recurrence detection,and therapeutic decision making of DLBCL. Other imaging modalities including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and conventional radiography are also used in the evaluation of lymphoma. MRI is useful for nervous system and musculoskeletal system involvement and is emerging as a radiation free alternative to PET/CT. This article provides a comprehensive review of both the functional and morphological imaging modalities, available in the management of DLBCL.
